Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Yann-Alexandre Vano, MD, Georges-Pompidou European Hospital, Paris, France, discusses his thoughts on immunotherapy combinations for renal cell cancer (RCC), highlighting a trial he was involved with called BIONIKK, which studied the use of biomarkers to aid therapy choice. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.